We are live on
!
Find out more
RVNC
Revance Therapeutics, Inc.
RVNC
RVNC
Delisted
RVNC was delisted on the 5th of February, 2025.
173 hedge funds and large institutions have $209M invested in Revance Therapeutics, Inc. in 2024 Q2 according to their latest regulatory filings, with 27 funds opening new positions, 63 increasing their positions, 42 reducing their positions, and 41 closing their positions.
New
Increased
Maintained
Reduced
Closed
103% more call options, than puts
Call options by funds: $1.57M | Put options by funds: $775K
50% more repeat investments, than reductions
Existing positions increased: 63 | Existing positions reduced: 42
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
8% less funds holding
Funds holding: 188 → 173 (-15)
34% less first-time investments, than exits
New positions opened: 27 | Existing positions closed: 41
49% less capital invested
Capital invested by funds: $411M → $209M (-$202M)
Holders
173
Holders Change
-15
Holders Change %
-7.98%
% of All Funds
2.5%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
27
Increased
63
Reduced
42
Closed
41
Calls
$1.57M
Puts
$775K
Net Calls
+$797K
Net Calls Change
-$1.25M
Top Buyers
| 1 |
BlackRock
New York
|
+$4.28M |
| 2 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
+$2.81M |
| 3 |
N
Nuveen
Charlotte,
North Carolina
|
+$2.4M |
| 4 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$2.3M |
| 5 |
Millennium Management
New York
|
+$2.06M |
Top Sellers
| 1 |
Barclays
London,
United Kingdom
|
-$10.2M |
| 2 |
CIBC Asset Management
Toronto,
Ontario, Canada
|
-$8.56M |
| 3 |
SCM
Suvretta Capital Management
New York
|
-$5.26M |
| 4 |
OM
Opaleye Management
Boston,
Massachusetts
|
-$3.86M |
| 5 |
Marshall Wace
London,
United Kingdom
|
-$3.84M |
